Resilience to acquire bluebird’s clinical and commercial suspension lentiviral vector manufacturing facility in North Carolina, retaining all current employees at the site
Alliance designed to foster best in class cell therapy product and manufacturing innovation through risk-sharing and royalty-based model
bluebird to receive $110M upfront, preferred LVV manufacturing access and significantly reduce operational expenses over coming years
https://finance.yahoo.com/news/bluebird-bio-resilience-announce-strategic-120000678.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.